Laverock Therapeutics is expanding its therapeutic pipeline into in vivo [...]

Kupando has dosed the first patient in a Phase 1 [...]

Obsidian Therapeutics has enrolled the first patient in the registration-enabling [...]

A Phase 1/1b clinical trial has begun in Australia to [...]

Mestag Therapeutics has dosed the first patient in its Phase [...]

Eascra Biotech is advancing DNA-inspired nanomaterials developed with ISS National [...]

Kainova Therapeutics has dosed the first European patient in its [...]

Kainova Therapeutics has dosed the first patient in Europe in [...]

FoRx Therapeutics presents preclinical data on FORX-428, a PARG inhibitor [...]

One-carbon Therapeutics has signed a collaboration with Tempus to generate [...]